The Development and Application of Cellular Sensitivity Biomarkers for the Detection and Measurement of Toxic Effects in Normal and Malignant Cells From Patients Receiving High-Dose Meiphalan (L-PAM) With Autologous Peripheral Blood Progenitor Cell Rescue in the Treatment of Metastatic Breast Cancer.
Abstract
This study provides a unique setting for applying biomarkers of cellular sensitivity to monitor and analyze therapeutic versus toxic effects in high dose, single agent, cancer chemotherapy. SDG is a novel approach to detect and measure DNA damage. It was developed to evaluate effective doses of drugs with reference to administered dosage and damage to specific target tissues. The ultimate goal is to develop a system (1) to prescreen for optimal agents and doses and (2) to monitor responses in real-time for each woman individually. The report describes modifications to the methods proposed including the development and use of an advanced immunophenotyping technique. Results from experiments designed to establish procedural standards and quality controls in the test battery are presented. Repetitive assessments to detect and eliminate between tests error originating from controllable variables are described. A series of 16 figures provides data to attest that overall technical quality of the as says has been evaluated and optimized. The results indicate that, despite unavoidable delays, the project if on track and certain to deliver products that will contribute to the treatment of breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1995
- Accession Number
- ADB212989
Entities
People
- Atif M. Hussein
Organizations
- Duke University Hospital